Logo image
Back
Trivalent influenza vaccine and febrile adverse events in Australia, 2010: Clinical features and potential mechanisms
Journal article   Open access   Peer reviewed

Trivalent influenza vaccine and febrile adverse events in Australia, 2010: Clinical features and potential mechanisms

C.C. Blyth, A.J. Currie, S.P. Wiertsema, N. Conway, L.A.S. Kirkham, A. Fuery, F. Mascaro, G.C. Geelhoed and P.C. Richmond
Vaccine, Vol.29(32), pp.5107-5113
2011
DOI: https://doi.org/10.1016/j.vaccine.2011.05.054
pdf
influenza_vaccine_and_febrile_adverse_events.pdfDownloadView
Author’s Version Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

Introduction: Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010. We describe the epidemiology and clinical features of the adverse events and explore the biological basis for the adverse events using an in vitro model. Materials and Methods: Children presenting to a tertiary paediatric hospital in 2010 with adverse events within 72. h of TIV were retrospectively reviewed. Demographics, clinical features, physiological variables and outcomes were examined. Plasma cytokine and chemokine levels were examined in a subgroup of children with vaccine-related febrile convulsions. Peripheral blood mononuclear cells of age-matched children were stimulated with different TIV preparations. Inflammatory cytokine and chemokine analysis was performed on cultured supernatants. Results: Vaccine-related febrile adverse events were identified in 190 children. Most occurred in healthy children (median age: 1.5 years) within 12h of vaccination. Twenty-eight (14.7%) required hospital admission. High temperature ≥39.0°C (101/190; 53%), vomiting (120/190; 63%) and convulsions (38/190; 20%) were common. All children presenting had received Fluvax® or Fluvax Junior®.In the in vitro model, IFN-α, IL-1β, IL-6, IL-10, IP-10 and MIP-1α levels were significantly higher when measured at 6 and 24h in cultures stimulated with Fluvax® compared with alternative 2010 TIV preparations. Conclusions: Numerous febrile adverse events (including febrile seizures) were observed following Fluvax® or Fluvax Junior® in 2010. Clear differences in cytokine production were observed when peripheral blood mononuclear cells were stimulated with Fluvax® compared with alternate TIV preparations. Increased awareness of these potential adverse events is required to ensure earlier detection and prevention in the future.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

507 File views/ downloads
75 Record Views
42 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.104 Virology - General
1.104.126 Influenza
Web Of Science research areas
Immunology
Medicine, Research & Experimental
ESI research areas
Immunology
Logo image